NO985065L - Anvendelse av proteinkinase C-inhibitorer til Õ bedre den kliniske virkningen av onkolytiske midler og strÕlingsterapi - Google Patents

Anvendelse av proteinkinase C-inhibitorer til Õ bedre den kliniske virkningen av onkolytiske midler og strÕlingsterapi

Info

Publication number
NO985065L
NO985065L NO985065A NO985065A NO985065L NO 985065 L NO985065 L NO 985065L NO 985065 A NO985065 A NO 985065A NO 985065 A NO985065 A NO 985065A NO 985065 L NO985065 L NO 985065L
Authority
NO
Norway
Prior art keywords
inhibitors
improve
protein kinase
radiation therapy
clinical effect
Prior art date
Application number
NO985065A
Other languages
English (en)
Norwegian (no)
Other versions
NO985065D0 (no
Inventor
Michael R Jirousek
Lawrence E Stramm
Douglas Kirk Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO985065D0 publication Critical patent/NO985065D0/no
Publication of NO985065L publication Critical patent/NO985065L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO985065A 1996-05-01 1998-10-30 Anvendelse av proteinkinase C-inhibitorer til Õ bedre den kliniske virkningen av onkolytiske midler og strÕlingsterapi NO985065L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,738 US6232299B1 (en) 1996-05-01 1997-04-30 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
PCT/US1997/007801 WO1997040842A1 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Publications (2)

Publication Number Publication Date
NO985065D0 NO985065D0 (no) 1998-10-30
NO985065L true NO985065L (no) 1998-12-28

Family

ID=26688914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985065A NO985065L (no) 1996-05-01 1998-10-30 Anvendelse av proteinkinase C-inhibitorer til Õ bedre den kliniske virkningen av onkolytiske midler og strÕlingsterapi

Country Status (15)

Country Link
US (3) US6232299B1 (ru)
EP (1) EP0914135A4 (ru)
JP (1) JP2000510828A (ru)
KR (1) KR20000065223A (ru)
AU (1) AU718098B2 (ru)
BR (1) BR9710704A (ru)
CA (1) CA2253263A1 (ru)
CZ (1) CZ344398A3 (ru)
EA (1) EA199800971A1 (ru)
HU (1) HUP0100285A3 (ru)
IL (1) IL126768A0 (ru)
NO (1) NO985065L (ru)
NZ (1) NZ332563A (ru)
PL (1) PL330862A1 (ru)
WO (1) WO1997040842A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
DK1636585T3 (da) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
AU2004282219C1 (en) 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
JP4832426B2 (ja) 2004-04-02 2011-12-07 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ６，６−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CA2617898A1 (en) * 2005-08-09 2007-02-15 Martin Schuler Staurosporine derivatives for treating non-small cell lung cancer
PE20070435A1 (es) 2005-09-16 2007-06-13 Schering Corp Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2010536371A (ja) 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2012109415A1 (en) 2011-02-11 2012-08-16 Glaxosmithkline Llc Cathepsin c inhibitors
WO2012173841A1 (en) * 2011-06-07 2012-12-20 Dana-Farber Cancer Institute, Inc. Biomarker for pkc-iota activity and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
AU637014B2 (en) * 1990-11-02 1993-05-13 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
EP0664706A1 (en) * 1991-08-22 1995-08-02 Sphinx Pharmaceuticals Corporation Protein kinase c inhibition and novel compound balanol
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
CA2174431C (en) 1993-10-18 2005-12-06 Tomas Hudlicky Synthesis of sphingosines
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JPH07238044A (ja) 1993-12-07 1995-09-12 Eli Lilly & Co ビスインドリルマレイミドの改良合成法
PT817627E (pt) * 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP0763041A1 (en) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor

Also Published As

Publication number Publication date
EA199800971A1 (ru) 1999-04-29
CZ344398A3 (cs) 1999-07-14
AU718098B2 (en) 2000-04-06
KR20000065223A (ko) 2000-11-06
US6486179B2 (en) 2002-11-26
JP2000510828A (ja) 2000-08-22
EP0914135A4 (en) 2001-01-24
IL126768A0 (en) 1999-08-17
NZ332563A (en) 2000-08-25
US6232299B1 (en) 2001-05-15
US6288053B1 (en) 2001-09-11
HUP0100285A3 (en) 2003-05-28
NO985065D0 (no) 1998-10-30
US20010001791A1 (en) 2001-05-24
HUP0100285A2 (hu) 2001-09-28
CA2253263A1 (en) 1997-11-06
WO1997040842A1 (en) 1997-11-06
PL330862A1 (en) 1999-06-07
BR9710704A (pt) 1999-08-17
EP0914135A1 (en) 1999-05-12
AU3000297A (en) 1997-11-19

Similar Documents

Publication Publication Date Title
NO985065D0 (no) Anvendelse av proteinkinase C-inhibitorer til Õ bedre den kliniske virkningen av onkolytiske midler og strÕlingsterapi
IS5405A (is) Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
NO983147L (no) Anvendelse av en antagonist av PPAR-<alfa> og PPAR-<gamma> for behandling av syndrom X
NO972125L (no) Hemorroideblandinger og fremgangsmåte for anvendelse
NO960079D0 (no) Oligonukleotid modulasjon av proteinkinase C
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
NO992337L (no) Bicykliske arylkarboksamider og deres terapeutiske anvendelse
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO952781D0 (no) Potensiering av temozolomid i humane tumorceller
FI965204A (fi) Bromelaiinin lääkekäyttö
NO951825D0 (no) Vannbasert hårbehandlingspreparat og anvendelse av dette
NO991459L (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
IS5713A (is) Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
GB9708067D0 (en) Rapid and long lasting biocidal system and its use to the treatment of hard surfaces
NO970257D0 (no) Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer
IT232384Y1 (it) Apparecchiatura per ipotermia e/o ipertermia terapeutica.
FI963263A (fi) Bromelaiinin lääkinnällinen käyttö
NO983215D0 (no) Sammensetninger for behandling av hudpÕvirkninger og fremgangsmaate for dens fremstilling
NO20010786D0 (no) TPL-2/COT kinase og fremgangsmåter for anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application